ID110521156

DRUG2 trials

Sponsors

IlDong Pharmaceutical Co Ltd

Conditions

Healthy Adult Subjects

Phase 1

Single Ascending Oral Dose Phase 1 Study of ID110521156 in Healthy Adult Subjects

CompletedNCT06063291

IlDong Pharmaceutical Co LtdHealthy Adult Subjects

Start: 2023-11-20End: 2024-07-11Updated: 2024-11-25

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ID110521156 in Healthy Adult Subjects

RecruitingNCT06635226

IlDong Pharmaceutical Co LtdHealthy Adult Subjects

Start: 2024-11-13End: 2025-06-19Target: 36Updated: 2024-12-24

Related Papers

1682-P: ID110521156, a Novel Oral Small-Molecule GLP-1RA: Evidence of Favorable Safety Profile and Dose-Dependent Reduction in Body Weight and Glycemic Control after 28 Days of Treatment

Diabetes2026-06-05

1983-LB: A Phase 1 Study of ID110521156, a Small Molecule Glucagon-Like Peptide 1 Receptor Agonist, in Healthy Subjects

Diabetes2025-06-131 citations